DCC-2036
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
The receptor tyrosine kinase inhibitor, Tie2, has significant roles in endothelial signaling and angiogenesis, and is relevant in…
TPS2666 Background: Rebastinib is a potent, orally administered, kinase switch control inhibitor selectively targeting the tunica…
The paradigm-shifting clinical success of imatinib in the treatment of chronic myeloid leukemia (CML) established continuous…
In some types of tumors, malignant cells are highly dependent on the constitutive activation of a certain protein encoded by…
Th e introduction in clinical practice of tyrosine kinase inhibitors (TKIs) targeting the oncogenic BCR – ABL protein has had a…
The 21st century ushered in the dawn of a new era of targeted therapeutics and a dramatic shift in the management of chronic…
Abstract 601 Background. DCC-2036 is a novel and potent tyrosine kinase inhibitor (TKI) which binds to a novel region called the…
Abstract 3398 Chronic Myeloid Leukemia (CML) treatment was radically modified by the discovery of imatinib (IM), a selective…
Abstract 1226 Background: Mutations in the kinase domain (KD) of Abl represent the most common mechanism of resistance to…
Therapy with ATP-competitive ABL kinase inhibitors, including imatinib (Gleevec), dasatinib (Sprycel), and nilotinib (Tasigna…